此页面是自动翻译的，不保证翻译的准确性。请参阅 英文版 对于源文本。

在 75 岁或以上新诊断的弥漫性大 B 细胞淋巴瘤患者中测试 CC-486（口服阿扎胞苷）加标准药物治疗

2026年11月10日 更新者：National Cancer Institute (NCI)

在 75 岁或以上新诊断的弥漫性大 B 细胞淋巴瘤、IIIB 级滤泡性淋巴瘤、转化淋巴瘤和高级 B 的参与者中，R-MiniCHOP 联合或不联合 CC-486（口服阿扎胞苷）的 II/III 期随机研究-具有 MYC 和 BCL2 和/或 BCL6 重排的细胞淋巴瘤

This phase II/III trial compares the side effects and activity of oral azacitidine in combination with the standard drug therapy (reduced dose rituximab-cyclophosphamide, doxorubicin, vincristine, and prednisone [R-miniCHOP]) versus R-miniCHOP alone in treating patients 75 years or older with newly diagnosed diffuse large B cell lymphoma. R-miniCHOP includes a monoclonal antibody (a type of protein), called rituximab, which attaches to the lymphoma cells and may help the immune system kill these cells. R-miniCHOP also includes prednisone which is an anti-inflammatory medication and a combination of 3 chemotherapy drugs, cyclophosphamide, doxorubicin, and vincristine. These 3 chemotherapy drugs, as well as oral azacitidine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Combining oral azacitidine with R-miniCHOP may shrink the cancer or extend the time without disease symptoms coming back or extend patient's survival when compared to R-miniCHOP alone.

研究概览

地位

主动，不招人

条件

干预/治疗

详细说明

PRIMARY OBJECTIVES:

I. To determine if the addition of CC-486 (oral azacitidine) to R-miniCHOP results in excess toxicity compared to R-miniCHOP alone that would preclude the combination from being studied further. (Safety run-in) II. To determine if the CC-486 + R-miniCHOP regimen should be tested further (Phase III) against the control R-miniCHOP alone based on progression-free survival (PFS). (Phase II component) III. To compare the overall survival (OS) between CC-486 + R-miniCHOP and R-miniCHOP alone. (Phase III component)

SECONDARY OBJECTIVES:

I. To assess the feasibility of delivering at least 4 cycles of CC-486 with R-miniCHOP in this population.

II. To assess toxicity for CC-486 + R-miniCHOP and for R-miniCHOP. III. To compare complete response rates, as defined by Lugano 2014 classification, between CC-486 + R-miniCHOP and R-miniCHOP alone.

INTEGRATED CORRELATIVE GERIATRIC ASSESSMENTS:

I. To compare functioning as assessed by the S1918 Comprehensive Geriatric Assessment (S1918 CGA) between participants treated with CC-486 + R-miniCHOP versus R-miniCHOP alone.

II. To evaluate if frailty status (fit/unfit versus [vs] frail/superfrail) as assessed by the FIL tool is associated with OS.

III. To evaluate if frailty as measured by the FIL tool correlates with the summary frailty index as measured using components of the S1918 CGA.

BANKING OBJECTIVE:

I. To bank specimens for future correlative studies.

OUTLINE:

Beginning 7 days prior to starting [protocol treatment, all patients receive vincristine sulfate intravenously (IV) on day 1, and prednisone orally (PO) daily on days 1-7.

Patients are then randomized to 1 of 2 arms.

ARM I: Patients receive CC-486 PO for 7 days prior to cycle 1. Patients then receive CC-486 PO on days 8-21. Treatment repeats every 21 days for cycles 1-5 in the absence of disease progression or unacceptable toxicity. Patients also receive rituximab IV (or rituximab and hyaluronidase human subcutaneously [SC] for cycles 2-6), cyclophosphamide IV, doxorubicin hydrochloride IV, and vincristine sulfate IV on day 1, and prednisone PO on days 1-5. Treatment repeats every 21 days for cycles 1-6 (6 cycles total) in the absence of disease progression or unacceptable toxicity. Patients undergo echocardiography (ECHO) or multigated acquisition scan (MUGA) at screening and undergo positron emission tomography (PET)-computed tomography (CT) and blood sample collection throughout the study.

ARM II: Patients receive rituximab IV (or rituximab and hyaluronidase human SC for cycles 2-6), cyclophosphamide IV, doxorubicin hydrochloride IV, and vincristine sulfate IV on day 1, and prednisone PO on days 1-5. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo ECHO or MUGA at screening and undergo PET-CT and blood sample collection throughout the study.

After completion of study treatment, patients are followed up periodically until 5 years from the date of registration.

研究类型

介入性

注册 (估计的)

422

阶段

  • 阶段2
  • 第三阶段

联系人和位置

本节提供了进行研究的人员的详细联系信息，以及有关进行该研究的地点的信息。

学习地点

  • 美国
    • Arizona
      • Tucson、Arizona、美国、85719
        • Banner University Medical Center - Tucson
      • Tucson、Arizona、美国、85719
        • University of Arizona Cancer Center-North Campus
    • Arkansas
      • Little Rock、Arkansas、美国、72205
        • University of Arkansas for Medical Sciences
    • California
      • Anaheim、California、美国、92806
        • Kaiser Permanente-Anaheim
      • Baldwin Park、California、美国、91706
        • Kaiser Permanente-Baldwin Park
      • Bellflower、California、美国、90706
        • Kaiser Permanente-Bellflower
      • Beverly Hills、California、美国、90211
        • Tower Cancer Research Foundation
      • Costa Mesa、California、美国、92627
        • UC Irvine Health Cancer Center-Newport
      • Duarte、California、美国、91010
        • City of Hope Comprehensive Cancer Center
      • Fontana、California、美国、92335
        • Kaiser Permanente-Fontana
      • Harbor City、California、美国、90710
        • Kaiser Permanente South Bay
      • Huntington Beach、California、美国、92648
        • City of Hope Seacliff
      • Irvine、California、美国、92618
        • Kaiser Permanente-Irvine
      • Irvine、California、美国、92618
        • City of Hope at Irvine Lennar
      • Lancaster、California、美国、93534
        • City of Hope Antelope Valley
      • Long Beach、California、美国、90822
        • Tibor Rubin VA Medical Center
      • Long Beach、California、美国、90813
        • City of Hope at Long Beach Elm
      • Los Angeles、California、美国、90048
        • Cedars-Sinai Medical Center
      • Los Angeles、California、美国、90027
        • Kaiser Permanente Los Angeles Medical Center
      • Los Angeles、California、美国、90034
        • Kaiser Permanente West Los Angeles
      • Newport Beach、California、美国、92660
        • City of Hope Newport Beach
      • Ontario、California、美国、91761
        • Kaiser Permanente-Ontario
      • Orange、California、美国、92868
        • UC Irvine Health/Chao Family Comprehensive Cancer Center
      • Palo Alto、California、美国、94304
        • Stanford Cancer Institute Palo Alto
      • Panorama City、California、美国、91402
        • Kaiser Permanente - Panorama City
      • Riverside、California、美国、92505
        • Kaiser Permanente-Riverside
      • San Diego、California、美国、92120
        • Kaiser Permanente-San Diego Zion
      • San Marcos、California、美国、92078
        • Kaiser Permanente-San Marcos
      • San Mateo、California、美国、94402
        • UCSF Cancer Center - San Mateo
      • South Pasadena、California、美国、91030
        • City of Hope South Pasadena
      • Torrance、California、美国、90503
        • City of Hope South Bay
      • Upland、California、美国、91786
        • City of Hope Upland
      • Woodland Hills、California、美国、91367
        • Kaiser Permanente-Woodland Hills
    • Colorado
      • Golden、Colorado、美国、80401
        • Lutheran Hospital - Cancer Centers of Colorado
    • Delaware
      • Newark、Delaware、美国、19713
        • Helen F Graham Cancer Center
      • Newark、Delaware、美国、19713
        • Delaware Clinical and Laboratory Physicians PA
      • Newark、Delaware、美国、19713
        • Medical Oncology Hematology Consultants PA
    • Florida
      • Miami、Florida、美国、33136
        • University of Miami Miller School of Medicine-Sylvester Cancer Center
    • Georgia
      • Atlanta、Georgia、美国、30308
        • Emory University Hospital Midtown
      • Atlanta、Georgia、美国、30322
        • Emory University Hospital/Winship Cancer Institute
      • Atlanta、Georgia、美国、30342
        • Emory Saint Joseph's Hospital
      • Augusta、Georgia、美国、30912
        • Augusta University Medical Center
    • Hawaii
      • Honolulu、Hawaii、美国、96813
        • Queen's Medical Center
      • Honolulu、Hawaii、美国、96813
        • Hawaii Cancer Care Inc - Waterfront Plaza
      • Honolulu、Hawaii、美国、96813
        • Queen's Cancer Cenrer - POB I
      • Honolulu、Hawaii、美国、96813
        • Straub Clinic and Hospital
      • Honolulu、Hawaii、美国、96817
        • Queen's Cancer Center - Kuakini
      • ‘Aiea、Hawaii、美国、96701
        • Hawaii Cancer Care - Westridge
      • ‘Aiea、Hawaii、美国、96701
        • Pali Momi Medical Center
    • Illinois
      • Centralia、Illinois、美国、62801
        • Centralia Oncology Clinic
      • Chicago、Illinois、美国、60611
        • Northwestern University
      • Chicago、Illinois、美国、60637
        • University of Chicago Comprehensive Cancer Center
      • Chicago、Illinois、美国、60612
        • University of Illinois
      • Danville、Illinois、美国、61832
        • Carle at The Riverfront
      • DeKalb、Illinois、美国、60115
        • Northwestern Medicine Cancer Center Kishwaukee
      • Decatur、Illinois、美国、62526
        • Decatur Memorial Hospital
      • Decatur、Illinois、美国、62526
        • Cancer Care Specialists of Illinois - Decatur
      • Effingham、Illinois、美国、62401
        • Crossroads Cancer Center
      • Effingham、Illinois、美国、62401
        • Carle Physician Group-Effingham
      • Evanston、Illinois、美国、60201
        • NorthShore University HealthSystem-Evanston Hospital
      • Geneva、Illinois、美国、60134
        • Northwestern Medicine Cancer Center Delnor
      • Glenview、Illinois、美国、60026
        • NorthShore University HealthSystem-Glenbrook Hospital
      • Glenview、Illinois、美国、60026
        • Northwestern Medicine Glenview Outpatient Center
      • Grayslake、Illinois、美国、60030
        • Northwestern Medicine Grayslake Outpatient Center
      • Highland Park、Illinois、美国、60035
        • NorthShore University HealthSystem-Highland Park Hospital
      • Lake Forest、Illinois、美国、60045
        • Northwestern Medicine Lake Forest Hospital
      • Mattoon、Illinois、美国、61938
        • Carle Physician Group-Mattoon/Charleston
      • New Lenox、Illinois、美国、60451
        • UC Comprehensive Cancer Center at Silver Cross
      • O'Fallon、Illinois、美国、62269
        • Cancer Care Center of O'Fallon
      • Orland Park、Illinois、美国、60462
        • University of Chicago Medicine-Orland Park
      • Orland Park、Illinois、美国、60462
        • Northwestern Medicine Orland Park
      • Peoria、Illinois、美国、61615
        • Illinois CancerCare-Peoria
      • Shiloh、Illinois、美国、62269
        • Memorial Hospital East
      • Urbana、Illinois、美国、61801
        • Carle Cancer Center
      • Warrenville、Illinois、美国、60555
        • Northwestern Medicine Cancer Center Warrenville
    • Iowa
      • Ames、Iowa、美国、50010
        • McFarland Clinic - Ames
      • Ankeny、Iowa、美国、50023
        • UI Health Care Mission Cancer and Blood - Ankeny Clinic
      • Clive、Iowa、美国、50325
        • UI Health Care Mission Cancer and Blood - West Des Moines Clinic
      • Des Moines、Iowa、美国、50309
        • Iowa Methodist Medical Center
      • Des Moines、Iowa、美国、50309
        • UI Health Care Mission Cancer and Blood - Des Moines Clinic
      • Des Moines、Iowa、美国、50314
        • UI Health Care Mission Cancer and Blood - Laurel Clinic
    • Louisiana
      • Monroe、Louisiana、美国、71202
        • Ochsner LSU Health Monroe Medical Center
      • Shreveport、Louisiana、美国、71103
        • LSU Health Sciences Center at Shreveport
    • Massachusetts
      • Boston、Massachusetts、美国、02111
        • Tufts Medical Center
    • Michigan
      • Ann Arbor、Michigan、美国、48106
        • Trinity Health Saint Joseph Mercy Hospital Ann Arbor
      • Brighton、Michigan、美国、48114
        • Trinity Health IHA Medical Group Hematology Oncology - Brighton
      • Brighton、Michigan、美国、48114
        • Trinity Health Medical Center - Brighton
      • Canton、Michigan、美国、48188
        • Trinity Health IHA Medical Group Hematology Oncology - Canton
      • Canton、Michigan、美国、48188
        • Trinity Health Medical Center - Canton
      • Chelsea、Michigan、美国、48118
        • Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital
      • Chelsea、Michigan、美国、48118
        • Chelsea Hospital
      • Livonia、Michigan、美国、48154
        • Trinity Health Saint Mary Mercy Livonia Hospital
      • Livonia、Michigan、美国、48154
        • Hope Cancer Clinic
      • Ypsilanti、Michigan、美国、48197
        • Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus
      • Ypsilanti、Michigan、美国、48106
        • Huron Gastroenterology PC
    • Minnesota
      • Deer River、Minnesota、美国、56636
        • Essentia Health - Deer River Clinic
      • Duluth、Minnesota、美国、55805
        • Essentia Health Cancer Center
      • Hibbing、Minnesota、美国、55746
        • Essentia Health Hibbing Clinic
      • Sandstone、Minnesota、美国、55072
        • Essentia Health Sandstone
      • Virginia、Minnesota、美国、55792
        • Essentia Health Virginia Clinic
    • Mississippi
      • Oxford、Mississippi、美国、38655
        • Baptist Memorial Hospital and Cancer Center-Oxford
      • Southhaven、Mississippi、美国、38671
        • Baptist Memorial Hospital and Cancer Center-Desoto
    • Missouri
      • Cape Girardeau、Missouri、美国、63703
        • Saint Francis Medical Center
      • Chesterfield、Missouri、美国、63017
        • Saint Luke's Hospital
      • City of Saint Peters、Missouri、美国、63376
        • Siteman Cancer Center at Saint Peters Hospital
      • Creve Coeur、Missouri、美国、63141
        • Siteman Cancer Center at West County Hospital
      • Saint Joseph、Missouri、美国、64506
        • Heartland Regional Medical Center
      • St Louis、Missouri、美国、63110
        • Washington University School of Medicine
      • St Louis、Missouri、美国、63129
        • Siteman Cancer Center-South County
      • St Louis、Missouri、美国、63136
        • Siteman Cancer Center at Christian Hospital
    • Nebraska
      • Lincoln、Nebraska、美国、68516
        • Cancer Partners of Nebraska
    • New Jersey
      • Basking Ridge、New Jersey、美国、07920
        • Memorial Sloan Kettering Basking Ridge
      • Englewood、New Jersey、美国、07631
        • Englewood Hospital and Medical Center
      • Lakewood、New Jersey、美国、08701
        • Monmouth Medical Center Southern Campus
      • Long Branch、New Jersey、美国、07740
        • Monmouth Medical Center
      • Middletown、New Jersey、美国、07748
        • Memorial Sloan Kettering Monmouth
      • Montvale、New Jersey、美国、07645
        • Memorial Sloan Kettering Bergen
      • New Brunswick、New Jersey、美国、08903
        • Rutgers Cancer Institute of New Jersey
      • Newark、New Jersey、美国、07112
        • Newark Beth Israel Medical Center
      • Toms River、New Jersey、美国、08755
        • Community Medical Center
    • New York
      • Buffalo、New York、美国、14263
        • Roswell Park Cancer Institute
      • Commack、New York、美国、11725
        • Memorial Sloan Kettering Commack
      • Glens Falls、New York、美国、12801
        • Glens Falls Hospital
      • Harrison、New York、美国、10604
        • Memorial Sloan Kettering Westchester
      • Mineola、New York、美国、11501
        • NYU Langone Hospital - Long Island
      • New York、New York、美国、10065
        • Memorial Sloan Kettering Cancer Center
      • New York、New York、美国、10032
        • NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
      • New York、New York、美国、10065
        • NYP/Weill Cornell Medical Center
      • New York、New York、美国、10016
        • Laura and Isaac Perlmutter Cancer Center at NYU Langone
      • Oswego、New York、美国、13126
        • Upstate Cancer Center at Oswego
      • Syracuse、New York、美国、13210
        • State University of New York Upstate Medical University
      • Uniondale、New York、美国、11553
        • Memorial Sloan Kettering Nassau
      • Verona、New York、美国、13478
        • Upstate Cancer Center at Verona
    • North Carolina
      • Chapel Hill、North Carolina、美国、27599
        • UNC Lineberger Comprehensive Cancer Center
    • Ohio
      • Cleveland、Ohio、美国、44195
        • Cleveland Clinic Foundation
      • Cleveland、Ohio、美国、44111
        • Cleveland Clinic Cancer Center/Fairview Hospital
      • Columbus、Ohio、美国、43210
        • Ohio State University Comprehensive Cancer Center
      • Dayton、Ohio、美国、45415
        • Dayton Physician LLC - Englewood
      • Independence、Ohio、美国、44131
        • Cleveland Clinic Cancer Center Independence
      • Kettering、Ohio、美国、45409
        • Greater Dayton Cancer Center
      • Mansfield、Ohio、美国、44906
        • Cleveland Clinic Cancer Center Mansfield
      • Mayfield Heights、Ohio、美国、44124
        • Hillcrest Hospital Cancer Center
      • Sandusky、Ohio、美国、44870
        • North Coast Cancer Care
      • Strongsville、Ohio、美国、44136
        • Cleveland Clinic Cancer Center Strongsville
      • Warrensville Heights、Ohio、美国、44122
        • South Pointe Hospital
      • Wooster、Ohio、美国、44691
        • Cleveland Clinic Wooster Family Health and Surgery Center
    • Oklahoma
      • Lawton、Oklahoma、美国、73505
        • Cancer Centers of Southwest Oklahoma Research
      • Oklahoma City、Oklahoma、美国、73104
        • University of Oklahoma Health Sciences Center
    • Oregon
      • Portland、Oregon、美国、97225
        • Providence Saint Vincent Medical Center
      • Portland、Oregon、美国、97239
        • Portland VA Medical Center
    • South Carolina
      • Charleston、South Carolina、美国、29425
        • Medical University of South Carolina
      • Greenville、South Carolina、美国、29607
        • Saint Francis Cancer Center
      • Greenville、South Carolina、美国、29601
        • Saint Francis Hospital
    • Tennessee
      • Memphis、Tennessee、美国、38120
        • Baptist Memorial Hospital and Cancer Center-Memphis
    • Utah
      • Salt Lake City、Utah、美国、84112
        • Huntsman Cancer Institute/University of Utah
      • Salt Lake City、Utah、美国、84148
        • George E Wahlen Department of Veterans Affairs Medical Center
    • Virginia
      • Charlottesville、Virginia、美国、22908
        • University of Virginia Cancer Center
      • Fairfax、Virginia、美国、22031
        • Inova Schar Cancer Institute
      • Richmond、Virginia、美国、23298
        • VCU Massey Comprehensive Cancer Center
    • Washington
      • Bellevue、Washington、美国、98004
        • FHCC Overlake
      • Kirkland、Washington、美国、98034
        • FHCC at EvergreenHealth
      • Seattle、Washington、美国、98133
        • FHCC at Northwest Hospital
    • West Virginia
      • Charleston、West Virginia、美国、25304
        • Vandalia Health/CAMC Institute for Academic Medicine
    • Wisconsin
      • Ashland、Wisconsin、美国、54806
        • Duluth Clinic Ashland
      • Eau Claire、Wisconsin、美国、54701
        • Marshfield Medical Center-EC Cancer Center
      • Green Bay、Wisconsin、美国、54301
        • Saint Vincent Hospital Cancer Center Green Bay
      • Green Bay、Wisconsin、美国、54303
        • Saint Vincent Hospital Cancer Center at Saint Mary's
      • La Crosse、Wisconsin、美国、54601
        • Gundersen Lutheran Medical Center
      • Marshfield、Wisconsin、美国、54449
        • Marshfield Medical Center-Marshfield
      • Minocqua、Wisconsin、美国、54548
        • Marshfield Medical Center - Minocqua
      • Oconto Falls、Wisconsin、美国、54154
        • Saint Vincent Hospital Cancer Center at Oconto Falls
      • Rice Lake、Wisconsin、美国、54868
        • Marshfield Medical Center-Rice Lake
      • Sheboygan、Wisconsin、美国、53081
        • Saint Vincent Hospital Cancer Center at Sheboygan
      • Stevens Point、Wisconsin、美国、54482
        • Marshfield Medical Center-River Region at Stevens Point
      • Sturgeon Bay、Wisconsin、美国、54235-1495
        • Saint Vincent Hospital Cancer Center at Sturgeon Bay
      • Weston、Wisconsin、美国、54476
        • Marshfield Medical Center - Weston

参与标准

研究人员寻找符合特定描述的人，称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

75年 及以上 (年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Participants must have histologically or cytologically confirmed diffuse large B-cell lymphoma (DLBCL), Ann Arbor Stage IIX (bulky), III or IV. Participants with DLBCL transformed from follicular lymphoma (FL) or marginal zone lymphoma (MZL, including mucosa-associated lymphoid tissue [MALT] lymphomas), lymphoplasmacytic lymphoma (LPL), or nodular lymphocyte-predominant Hodgkin Lymphoma (NLPHL) are eligible. Participants with Grade IIIB follicular lymphoma (FL) or high-grade B-cell lymphomas with MYC and BCL2 and/or BCL6 rearrangements are also eligible. Participants with DLBCL that arose from prior CLL (Richter's transformation) are not eligible.

  • As defined by the World Health Organization (WHO), eligible lymphoma subtypes include the following:

    • DLBCL, not otherwise specified (NOS)
    • DLBCL, germinal-center B-cell type (GCB)
    • DLBCL, activated B-cell type (ABC)
    • T-cell histiocyte-rich B-cell lymphomas (THRBCL)
    • Primary cutaneous DLBCL, leg type
    • Intravascular large B cell lymphoma
    • EBV+ DLBCL, NOS
    • DLBCL associated with chronic inflammation
    • HHV8+ DLBCL, NOS
    • High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements
    • High grade B-cell lymphoma, NOS
    • Follicular lymphoma grade 3b

  • Participants must have staging imaging performed within 28 days prior to registration, as follows. PET-CT baseline scans are strongly preferred; diagnostic quality magnetic resonance imaging (MRI), contrast-enhanced CT, or contrast-enhanced MRI scans are also acceptable if PET-CT is not feasible at baseline. Note: PET-CT will be required at end of treatment (EOT) and progression for response assessment. Participants must have measurable disease (at least one lesion with longest diameter ≥ 1.5 cm). All measurable lesions (longest diameter >= 1.5 cm) must be assessed within 28 days prior to registration. Tests to assess non-measurable disease must be performed within 42 days prior to registration.

  • Participants with known human immunodeficiency virus (HIV)-infection are eligible providing they are on effective anti-retroviral therapy and have undetectable viral load at their most recent viral load test (must be within 26 weeks prior to registration). Participants with known HIV must have a CD4 count checked within 28 days prior to registration, but may proceed with therapy regardless of CD4 count.

  • All participants must be screened for chronic hepatitis B virus (HBV) within 28 days prior to registration. Participants with known HBV infection (positive serology) must also have a HBV viral load performed within 28 days prior to registration, and participants must have an undetectable HBV viral load on suppressive therapy within 28 days prior to registration. Participants found to be HBV carriers during screening are eligible and must receive standard of care prophylaxis. Participants with active hepatitis B (HBV viral load > 500 IU/mL) within 28 days prior to registration are not eligible

  • Participants with a known history of hepatitis C virus (HCV) infection must have an undetectable HCV viral load within in 28 days prior to registration

  • Participants must not have known lymphomatous involvement of the central nervous system (CNS)

  • Participants must not have active inflammatory bowel disease (such as, Crohn's disease, ulcerative colitis), celiac disease (i.e., sprue), prior gastrectomy or upper bowel removal, or any other gastrointestinal disorder or defect that would interfere with the absorption, distribution, metabolism, or excretion of the study drug and/or predispose the subject to an increased risk of gastrointestinal toxicity

  • Participants must not have a history of acute leukemia having been treated with intensive induction therapy. Participants with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial

  • Participants must not have received any prior cytotoxic chemotherapy or rituximab for treatment of the newly diagnosed DLBCL except for the pre-phase treatment (within specified dose range) that may have either started before or may start after registration to S1918. Inhaled, nasal, and topical steroid use is allowed. Prior cytotoxic chemotherapy and/or antibody therapy for an indolent lymphoma prior to transformation is allowed. Up to 4 doses of intrathecal (IT) chemotherapy administered for central nervous system (CNS) prophylaxis is allowed in addition to protocol therapy. High-dose intravenous methotrexate is not allowed.

  • Participants must not have received more than a cumulative of dose 250 mg/m^2 of prior doxorubicin (or equivalent dose of another anthracycline, such as epirubicin) therapy (at any time prior to registration).

  • Participants must not currently be receiving any other investigational agents

  • Participant must not have a history of allergic reactions attributed to azacitidine, mannitol, or other hypomethylating agents

  • Participants must be age ≥ 75

  • Participants must have a Zubrod performance status of 0-2

  • Participants must have adequate renal function, as demonstrated by a creatinine clearance, calculated by the Cockcroft and Gault formula, of >= 30 ml/min that was obtained within 28 days prior to registration

  • Aspartate aminotransferase (AST) =< 2.5 x institutional upper limit of normal (IULN), alanine aminotransferase (ALT) =< 2.5 x IULN (within 28 days prior to registration)

  • Total bilirubin =< 2 x institutional upper limit of normal (IULN), unless due to Gilbert's disease, hemolysis, or lymphomatous involvement of liver (within 28 days prior to registration). Note: If total bilirubin is elevated, and direct bilirubin is subsequently performed (within 28 days prior to registration) and resulted to be =< 2 x IULN, the participant will be considered eligible

  • Absolute neutrophil count (ANC) >= 1000/mcL (within 28 days prior to registration)

  • Platelets >= 75,000/mcL (within 28 days prior to registration)

  • Hemoglobin (Hgb) >= 8 g/ dL (within 28 days prior to registration)

  • If there is a documented lymphomatous involvement of the bone marrow, bone marrow function within 28 days prior to registration, as evidenced by:

    • ANC >= 500/mcL
    • Platelets >= 50,000/mcL
    • Hgb >= 8 g/ dL

  • Participants must have a left ventricular ejection (LVEF) fraction >= 45% as measured by echocardiogram or radionuclide (multigated acquisition scan [MUGA]) ventriculography within 56 days prior to registration

  • For the duration of the study treatment period and for at least 4 months following the last dose of study drug, male participants must agree to use effective contraceptive methods during sexual contact with a female of childbearing potential (FCBP) and must agree to refrain from semen or sperm donation during the same timeframe. Effective contraceptive methods include a history of vasectomy, use of hormonal contraception or an intrauterine device (IUD) by the female partner, or use of condoms

    • A FCBP is a sexually mature woman who: 1) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally postmenopausal for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months)

  • Participants must not have active infection (systemic fungal, bacterial, or viral infection) that is not controlled (defined as ongoing signs/symptoms related the infection without improvement despite appropriate antibiotics, antiviral therapy, and/or other treatment)

  • Participants must not have active cardiac disease within 26 weeks prior to registration, including: symptomatic congestive heart failure (New York Heart Association [NYHA] class 4), unstable angina pectoris, hemodynamically unstable cardiac arrhythmia, or myocardial infarction

  • Participants must not have >= grade 2 neuropathy, by Common Terminology Criteria for Adverse Events (CTCAE) version (v.) 5.0, within 28 days prior to registration

  • Participants must not have any other known uncontrolled intercurrent illness including, but not limited to ongoing psychiatric illness/social situations that would limit compliance with study requirements

  • Participants must not have a concurrent primary malignancy undergoing active therapy. Exceptions: participants may have non-melanomatous skin cancers requiring only surgical intervention. Participants may have a history of early stage breast cancer or prostate cancer in remission after surgical and/or radiation therapy on adjuvant hormonal therapy only

学习计划

本节提供研究计划的详细信息，包括研究的设计方式和研究的衡量标准。

研究是如何设计的？

设计细节

  • 主要用途：治疗
  • 分配：随机化
  • 介入模型：并行分配
  • 屏蔽：无（打开标签）

武器和干预

参与者组/臂
干预/治疗
实验性的：Arm I (oral azacitidine, R-miniCHOP)

Patients receive CC-486 PO for 7 days prior to cycle 1. Patients then receive CC-486 PO on days 8-21. Treatment repeats every 21 days for cycles 1-5 in the absence of disease progression or unacceptable toxicity. Patients also receive rituximab IV (or rituximab and hyaluronidase human SC for cycles 2-6), cyclophosphamide IV, doxorubicin hydrochloride IV, and vincristine sulfate IV on day 1, and prednisone PO on days 1-5. Treatment repeats every 21 days for cycles 1-6 (6 cycles total) in the absence of disease progression or unacceptable toxicity. Patients undergo ECHO or MUGA at screening and undergo PET-CT and blood sample collection throughout the study.
药品：Cyclophosphamide

Given IV

其他名称：
  • 胞毒素
  • CTX
  • (-)-环磷酰胺
  • 2H-1,3,2-氧氮杂膦，2-[双（2-氯乙基）氨基]四氢-，2-氧化物，一水合物
  • 卡洛生
  • 环磷酰胺
  • 环草醛
  • 克拉芬
  • CP一水合物
  • 循环电池
  • 环胚素
  • 环爆碱
  • 环磷酰胺一水合物
  • 环磷烷
  • 环磷脂
  • 环素
  • 环孢菌素
  • 胞磷
  • 胞磷烷
  • 磷脂龙
  • Genoxal
  • Genuxal
  • 雷多西那
  • 米托生
  • 新星
  • 重免疫
  • 赛克磷酰胺
  • WR- 138719
  • 阿斯塔B 518
  • B-518
  • WR-138719
  • 乙518
  • B518
  • WR 138719
  • WR138719
  • Frindovyx
药品：Doxorubicin Hydrochloride

Given IV

其他名称：
  • 阿霉素
  • 5,12-并萘二酮，10-[(3-氨基-2,3,6-三脱氧-α-L-来氧代-己吡喃糖基)氧基]-7,8, 9,10-四氢-6,8,11-三羟基-8-(羟基乙酰基)-1-甲氧基-, 盐酸盐, (8S-cis)- (9CI)
  • 广告管理公司
  • 盐酸阿霉素
  • 阿霉素 PFS
  • 阿霉素RDF
  • 阿霉素，盐酸盐
  • Adriblastina
  • 阿得拉碱
  • 阿地美达
  • 氯霉素
  • DOX
  • DOXO细胞
  • 多索伦
  • 阿霉素盐酸盐
  • 农杆菌
  • FI 106
  • FI-106
  • 羟基柔红霉素
  • 橡胶
  • FI106
药品：Prednisone

Given PO

其他名称：
  • 达美松
  • 奥拉松
  • .delta.1-可的松
  • 1, 2-脱氢可的松
  • 阿达松
  • 皮质醇
  • 达考汀
  • 德考坦
  • 去氧硫醇
  • 德克顿
  • Delta 1-可的松
  • 三角穹顶
  • 三角可烯
  • 三角可的松
  • 三角洲脱氢可的松
  • 德尔蒂森
  • 三角洲
  • 经济松
  • 利沙克特
  • 美保生-F
  • 麦考坦
  • 奥菲索罗纳
  • 帕纳福特
  • 松脂-S
  • 伞骨
  • Perrigo 泼尼松
  • 预测
  • 泼尼松-M
  • 泼尼可特
  • 泼尼地布
  • 泼尼龙加
  • 预付款
  • 泼尼松 Intensol
  • 泼尼松
  • 泼尼通
  • 普罗米芬
  • 雷约斯
  • 伺服松
  • SK-泼尼松
程序：Biospecimen Collection

Undergo blood sample collection

其他名称：
  • 生物样本采集
  • 收集的生物样本
  • 标本采集
  • 样本收集
生物：Rituximab

Given IV

其他名称：
  • 利妥昔单抗
  • 美罗华
  • 总部基地 798
  • BI 695500
  • C2B8单克隆抗体
  • 嵌合抗 CD20 抗体
  • CT-P10
  • IDEC-102
  • IDEC-C2B8
  • IDEC-C2B8单克隆抗体
  • 单克隆抗体IDEC-C2B8
  • PF-05280586
  • 里亚布尼
  • 利妥昔单抗ABBS
  • 利妥昔单抗ARRX
  • 利妥昔单抗生物类似药 ABP 798
  • 利妥昔单抗生物仿制药 BI 695500
  • 利妥昔单抗生物类似药 CT-P10
  • 利妥昔单抗生物类似药 GB241
  • 利妥昔单抗生物仿制药 IBI301
  • 利妥昔单抗生物类似药 JHL1101
  • 利妥昔单抗生物仿制药 PF-05280586
  • 利妥昔单抗生物类似药 RTXM83
  • 利妥昔单抗生物仿制药 SAIT101
  • 利妥昔单抗生物仿制药 SIBP-02
  • 利妥昔单抗生物类似药 TQB2303
  • 利妥昔单抗PVVR
  • 利妥昔单抗-arrx
  • 利妥昔单抗-pvvr
  • RTXM83
  • Ruxience
  • 特鲁希玛
  • 里克松
  • 伊克达尔
  • 马布塔斯
  • 利妥昔单抗-abbs
  • BI-695500
  • BI695500
  • 闪电战
  • IDEC 102
  • IDEC102
  • PF 05280586
  • PF05280586
  • 里特维亚
  • 利妥昔单抗-blit
  • 利西名
  • RTXM 83
  • RTXM-83
  • ABP-798
  • ABP798
  • CT P10
  • CTP10
  • 2013年大奖赛
  • GP-2013
  • GP2013
  • 利妥昔单抗生物仿制药 GP2013
药品：Vincristine Sulfate

Given IV

其他名称：
  • 致癌素
  • 基克里斯汀
  • 硫酸亮绿新碱
  • 硫酸白新碱
  • 长春
  • 长春甙
  • 万可乐
  • 硫酸长春新碱
其他：Questionnaire Administration

Ancillary studies

程序：Echocardiography Test

Undergo ECHO

其他名称：
  • 超声心动图
  • 欧共体
程序：Multigated Acquisition Scan

Undergo MUGA

其他名称：
  • 血池扫描
  • 平衡放射性核素血管造影
  • 门控血池成像
  • 穆加
  • 放射性核素脑室造影
  • 导航导航仪
  • 司马扫描
  • 同步多门采集扫描
  • 穆加扫描
  • 多门控采集扫描
  • 放射性核素脑室造影扫描
  • 门控心池扫描
  • RNV扫描
程序：Positron Emission Tomography

Undergo PET-CT

其他名称：
  • 医学成像、正电子发射断层扫描
  • 宠物
  • 宠物扫描
  • 正电子发射断层扫描
  • PT
  • 正电子发射断层扫描（程序）
生物：Rituximab and Hyaluronidase Human

Given SC

其他名称：
  • Rituxan 鬣蜥
  • 利妥昔单抗加透明质酸酶
  • 利妥昔单抗/透明质酸酶
  • 利妥昔单抗/透明质酸酶 人
程序：Computed Tomography

Undergo PET-CT

其他名称：
  • CT
  • 猫
  • 电脑扫描
  • 计算机轴向断层扫描
  • 计算机断层扫描
  • CT扫描
  • 断层扫描
  • 计算机轴向断层扫描（程序）
  • 计算机断层扫描 (CT) 扫描
  • 诊断猫扫描
  • 诊断猫扫描服务类型
药品：Oral Azacitidine

Given PO

其他名称：
  • 奥努雷格
  • CC-486
  • 阿扎胞苷口服
  • CC 486
  • CC486
有源比较器：Arm II (R-miniCHOP)

Patients receive rituximab IV (or rituximab and hyaluronidase human SC for cycles 2-6), cyclophosphamide IV, doxorubicin hydrochloride IV, and vincristine sulfate IV on day 1, and prednisone PO on days 1-5. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo ECHO or MUGA at screening and undergo PET-CT and blood sample collection throughout the study.
药品：Cyclophosphamide

Given IV

其他名称：
  • 胞毒素
  • CTX
  • (-)-环磷酰胺
  • 2H-1,3,2-氧氮杂膦，2-[双（2-氯乙基）氨基]四氢-，2-氧化物，一水合物
  • 卡洛生
  • 环磷酰胺
  • 环草醛
  • 克拉芬
  • CP一水合物
  • 循环电池
  • 环胚素
  • 环爆碱
  • 环磷酰胺一水合物
  • 环磷烷
  • 环磷脂
  • 环素
  • 环孢菌素
  • 胞磷
  • 胞磷烷
  • 磷脂龙
  • Genoxal
  • Genuxal
  • 雷多西那
  • 米托生
  • 新星
  • 重免疫
  • 赛克磷酰胺
  • WR- 138719
  • 阿斯塔B 518
  • B-518
  • WR-138719
  • 乙518
  • B518
  • WR 138719
  • WR138719
  • Frindovyx
药品：Doxorubicin Hydrochloride

Given IV

其他名称：
  • 阿霉素
  • 5,12-并萘二酮，10-[(3-氨基-2,3,6-三脱氧-α-L-来氧代-己吡喃糖基)氧基]-7,8, 9,10-四氢-6,8,11-三羟基-8-(羟基乙酰基)-1-甲氧基-, 盐酸盐, (8S-cis)- (9CI)
  • 广告管理公司
  • 盐酸阿霉素
  • 阿霉素 PFS
  • 阿霉素RDF
  • 阿霉素，盐酸盐
  • Adriblastina
  • 阿得拉碱
  • 阿地美达
  • 氯霉素
  • DOX
  • DOXO细胞
  • 多索伦
  • 阿霉素盐酸盐
  • 农杆菌
  • FI 106
  • FI-106
  • 羟基柔红霉素
  • 橡胶
  • FI106
药品：Prednisone

Given PO

其他名称：
  • 达美松
  • 奥拉松
  • .delta.1-可的松
  • 1, 2-脱氢可的松
  • 阿达松
  • 皮质醇
  • 达考汀
  • 德考坦
  • 去氧硫醇
  • 德克顿
  • Delta 1-可的松
  • 三角穹顶
  • 三角可烯
  • 三角可的松
  • 三角洲脱氢可的松
  • 德尔蒂森
  • 三角洲
  • 经济松
  • 利沙克特
  • 美保生-F
  • 麦考坦
  • 奥菲索罗纳
  • 帕纳福特
  • 松脂-S
  • 伞骨
  • Perrigo 泼尼松
  • 预测
  • 泼尼松-M
  • 泼尼可特
  • 泼尼地布
  • 泼尼龙加
  • 预付款
  • 泼尼松 Intensol
  • 泼尼松
  • 泼尼通
  • 普罗米芬
  • 雷约斯
  • 伺服松
  • SK-泼尼松
程序：Biospecimen Collection

Undergo blood sample collection

其他名称：
  • 生物样本采集
  • 收集的生物样本
  • 标本采集
  • 样本收集
生物：Rituximab

Given IV

其他名称：
  • 利妥昔单抗
  • 美罗华
  • 总部基地 798
  • BI 695500
  • C2B8单克隆抗体
  • 嵌合抗 CD20 抗体
  • CT-P10
  • IDEC-102
  • IDEC-C2B8
  • IDEC-C2B8单克隆抗体
  • 单克隆抗体IDEC-C2B8
  • PF-05280586
  • 里亚布尼
  • 利妥昔单抗ABBS
  • 利妥昔单抗ARRX
  • 利妥昔单抗生物类似药 ABP 798
  • 利妥昔单抗生物仿制药 BI 695500
  • 利妥昔单抗生物类似药 CT-P10
  • 利妥昔单抗生物类似药 GB241
  • 利妥昔单抗生物仿制药 IBI301
  • 利妥昔单抗生物类似药 JHL1101
  • 利妥昔单抗生物仿制药 PF-05280586
  • 利妥昔单抗生物类似药 RTXM83
  • 利妥昔单抗生物仿制药 SAIT101
  • 利妥昔单抗生物仿制药 SIBP-02
  • 利妥昔单抗生物类似药 TQB2303
  • 利妥昔单抗PVVR
  • 利妥昔单抗-arrx
  • 利妥昔单抗-pvvr
  • RTXM83
  • Ruxience
  • 特鲁希玛
  • 里克松
  • 伊克达尔
  • 马布塔斯
  • 利妥昔单抗-abbs
  • BI-695500
  • BI695500
  • 闪电战
  • IDEC 102
  • IDEC102
  • PF 05280586
  • PF05280586
  • 里特维亚
  • 利妥昔单抗-blit
  • 利西名
  • RTXM 83
  • RTXM-83
  • ABP-798
  • ABP798
  • CT P10
  • CTP10
  • 2013年大奖赛
  • GP-2013
  • GP2013
  • 利妥昔单抗生物仿制药 GP2013
药品：Vincristine Sulfate

Given IV

其他名称：
  • 致癌素
  • 基克里斯汀
  • 硫酸亮绿新碱
  • 硫酸白新碱
  • 长春
  • 长春甙
  • 万可乐
  • 硫酸长春新碱
其他：Questionnaire Administration

Ancillary studies

程序：Echocardiography Test

Undergo ECHO

其他名称：
  • 超声心动图
  • 欧共体
程序：Multigated Acquisition Scan

Undergo MUGA

其他名称：
  • 血池扫描
  • 平衡放射性核素血管造影
  • 门控血池成像
  • 穆加
  • 放射性核素脑室造影
  • 导航导航仪
  • 司马扫描
  • 同步多门采集扫描
  • 穆加扫描
  • 多门控采集扫描
  • 放射性核素脑室造影扫描
  • 门控心池扫描
  • RNV扫描
程序：Positron Emission Tomography

Undergo PET-CT

其他名称：
  • 医学成像、正电子发射断层扫描
  • 宠物
  • 宠物扫描
  • 正电子发射断层扫描
  • PT
  • 正电子发射断层扫描（程序）
生物：Rituximab and Hyaluronidase Human

Given SC

其他名称：
  • Rituxan 鬣蜥
  • 利妥昔单抗加透明质酸酶
  • 利妥昔单抗/透明质酸酶
  • 利妥昔单抗/透明质酸酶 人
程序：Computed Tomography

Undergo PET-CT

其他名称：
  • CT
  • 猫
  • 电脑扫描
  • 计算机轴向断层扫描
  • 计算机断层扫描
  • CT扫描
  • 断层扫描
  • 计算机轴向断层扫描（程序）
  • 计算机断层扫描 (CT) 扫描
  • 诊断猫扫描
  • 诊断猫扫描服务类型

研究衡量的是什么？

主要结果指标

结果测量
措施说明
大体时间
Excess toxicity as a result of adding oral azacitidine (CC-486) to reduced dose rituximab-cyclophosphamide, doxorubicin, vincristine, and prednisone (R-miniCHOP) (Safety run-in)
大体时间：Up to completion of cycle 6

Will determine if the addition of CC-486 to R-miniCHOP results in excess toxicity compared to R-miniCHOP alone that would preclude the combination from being studied further.
Up to completion of cycle 6
Progression-free survival (PFS) (Phase II)
大体时间：From date of registration to date of first observation of progressive disease according to the 2014 Lugano classification, or death due to any cause, assessed up to 1 year

Will determine if the CC-486 + R-miniCHOP regimen should be tested further (Phase III) against the control R-miniCHOP alone based on PFS. After accruing 130 patients (65 per arm, 21 months of accrual and potentially pausing accrual for 6 months follow-up to reach a target 63 events across arms), a one-sided stratified .10 log-rank test will inform a go/no-go decision based on sufficient evidence of efficacy to continue to the Phase III portion of the study.
From date of registration to date of first observation of progressive disease according to the 2014 Lugano classification, or death due to any cause, assessed up to 1 year
Overall survival (Phase III)
大体时间：From date of registration to date of death due to any cause, assessed up to 2 years

Will compare overall survival in the control arm of R-miniCHOP to the experimental arm of CC-486 (oral azacitidine) + R-miniCHOP. Will be evaluated using a 1-sided .025 level stratified logrank test.
From date of registration to date of death due to any cause, assessed up to 2 years

次要结果测量

结果测量
措施说明
大体时间
Metabolic complete response (CR)
大体时间：Up to end of cycle 6 or end of treatment

Will be defined using 2014 Lugano classification. Fisher's exact test will be used to compare CR rates between the experimental arm of CC-486 + R-miniCHOP and the control arm of R-miniCHOP alone.
Up to end of cycle 6 or end of treatment
Incidence of adverse events
大体时间：Until disease progression, assessed up to 5 years

Will be assessed using Common Terminology Criteria for Adverse Events version 5. The maximum Grade for each toxicity will be recorded for each patient, and frequency tables will be reviewed to determine toxicity patterns. Treatment-related toxicities between arms will be compared using Fisher's exact test.
Until disease progression, assessed up to 5 years
Overall survival (Phase III)
大体时间：From date of registration to date of death due to any cause, assessed up to 5 years

An additional secondary analysis of overall survival of the Phase III comparison will adjust for patients with identified double-hit phenotype in addition to the pre-specified stratification factors. Will also prospectively collect the number of days between diagnostic biopsy and cycle 1 day 1 of therapy for a pre-planned secondary analysis.
From date of registration to date of death due to any cause, assessed up to 5 years

其他结果措施

结果测量
措施说明
大体时间
Changes in function (Integrated Correlative Geriatric Assessments Substudy)
大体时间：From time of randomization up to 24 months after date of registration

Will be assessed by a Comprehensive Geriatric Assessment (Carolina Frailty Index [CFI] Score) between patients treated with CC-486 + R-miniCHOP and those treated with R-miniCHOP alone. Linear regression will be used for each examination, adjusting for the stratification factors from the clinical study and the baseline score (for the examination of change from 12 to 24 months, the 12-month score will be considered the baseline score). Although the number of timepoints is limited to 3, longitudinal assessments of the CFI Score over time will also be conducted using linear mixed models, adjusting for the stratification factors and the baseline score, with patient considered a random effect.
From time of randomization up to 24 months after date of registration
Frailty status (fit/unfit vs frail) (Integrated Correlative Geriatric Assessments Substudy)
大体时间：Baseline

Will evaluate if frailty status (fit/unfit versus frail) as assessed by the Italian Lymphoma Foundation (FIL) tool is associated with overall survival. Multivariable Cox regression will be conducted, adjusting for the stratification variables and the randomized treatment arm as covariates. Will also examine whether randomization to CC-486 + R-miniCHOP is associated with better overall survival compared to treatment with R-miniCHOP alone in the subset of fit and unfit patients. Multivariable Cox regression will be conducted, adjusting for the stratification variables as covariates.
Baseline
Frailty status (Integrated Correlative Geriatric Assessments Substudy)
大体时间：Up to 24 months after date of registration

Will evaluate if frailty status (fit/unfit versus frail) as assessed by the FIL tool correlates with the summary frailty indexed as measured by the S1918 Comprehensive Geriatric Assessment (CGA). In particular, agreement between the FIL and CGA will measured using an unweighted Kappa statistic; moderate or better agreement is defined as a Kappa coefficient of >= 0.41.
Up to 24 months after date of registration

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

赞助

National Cancer Institute (NCI)

调查人员

  • 首席研究员：Elizabeth A Brem、SWOG Cancer Research Network

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

一般刊物

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查，以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2021年5月20日

初级完成 (估计的)

2027年3月1日

研究完成 (估计的)

2027年3月1日

研究注册日期

首次提交

2021年3月13日

首先提交符合 QC 标准的

2021年3月13日

首次发布 (实际的)

2021年3月16日

研究记录更新

最后更新发布 (实际的)

2026年11月12日

上次提交的符合 QC 标准的更新

2026年11月10日

最后验证

2026年10月1日

更多信息

与本研究相关的术语

其他相关的 MeSH 术语

其他研究编号

  • NCI-2020-01256
  • U10CA180888 (美国 NIH 拨款/合同)
  • NCI-2020-01256 (注册表标识符：CTRP (Clinical Trial Reporting Program))
  • S1918 (其他标识符：CTEP)
  • S1918 (其他标识符：SWOG)

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)？

是的

IPD 计划说明

NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索，没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求，请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改，我们的网站上也会自动更新.

订阅